US FDA grants Fast Track designation to onvansertib for treatment of KRAS-mutated metastatic colorectal cancer

The oral Polo-like Kinase 1 (PLK1) inhibitor onvansertib is being investigated in combination with FOLFIRI/bevacizumab, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer, in an open-label Phase 1b/2 trial.

Source:

Biospace Inc.